Experimental treatment of stroke in spontaneously hypertensive rats by CD34+ and CD34- cord blood cells.
Human umbilical cord blood as a source of stem cells has recently been reported in experimental treatment of cerebral disorders. However, little is known about the nature of cells and cellular mechanisms leading to neurofunctional improvement. Here we investigated the potential of separated CD34(+) versus CD34(-) human umbilical cord blood cells (HUCBC) to promote functional recovery following stroke. The experiments were performed in spontaneously hypertensive (SH) rats, known for a risk profile comparable to stroke patients. After three weeks of behavioral training in the RotaRod and Beamwalk test arrays, stroke was induced by permanent middle cerebral artery occlusion (MCAO). For cell therapy, 1 x 10(6) cryopreserved cells were administered systemically between 8 and 10 hours after MCAO. The behavioral tests were performed together with a neurological severity score (mNSS) until day 29 to assess neurofunctional disabilities. Nearly complete functional remission was observed with both subpopulations CD34(+) as well as CD34(-) cells. To localize cells histologically, they were labeled with a fluorescence dye (CFSE) before injection. Again, after administration of CD34(+) as well as CD34(-) cells, CFSE labelled cells were found that accumulated in the border zone between the central necrosis of the ischemic lesion and functional brain tissue, thus indicating active attraction towards the lesion for both cell populations. Immunohistology with anti-CD68 and antibodies to human neuronal markers (NF-L, chromogranin) indicated an accumulation of human and rat monocytes in the border zone of the lesion while neuronal cells of human origin could not be detected in host brains.
Boltze
Johannes
J
Institute for Clinical Immunology and Transfusion Medicine, University of Leipzig, Germany.
Kowalski
Ina
I
Geiger
Kathrin
K
Reich
Doreen
D
Gunther
Albrecht
A
Buhrle
Christian
C
Egger
Dietmar
D
Kamprad
Manja
M
Emmrich
Frank
F
Eur Arch Psychiatry Clin Neurosci. 1993;242(4):179-83
8461343
Neurotox Res. 2003;5(5):355-68
14715454
Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14720-5
11121071
Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1968;259(2):211
4232694
Stroke. 1990 Apr;21(4):582-8
1691534
J Am Pharm Assoc Am Pharm Assoc. 1957 Mar;46(3):208-9
13502156
Blood. 1991 Jun 15;77(12):2591-6
1710512
Lancet Neurol. 2002 Jun;1(2):92-100
12849513
Immunol Cell Biol. 1999 Dec;77(6):499-508
10571670
Brain Res. 1996 Nov 11;739(1-2):88-96
8955928
Exp Neurol. 2001 Sep;171(1):109-15
11520125
J Cell Mol Med. 2004 Jan-Mar;8(1):45-58
15090260
Stroke. 2001 Nov;32(11):2682-8
11692034
ILAR J. 2003;44(2):85-95
12652003
J Neurotrauma. 1994 Apr;11(2):187-96
7932797
Blood Coagul Fibrinolysis. 1999 Jul;10(5):277-84
10456619
J Clin Invest. 2004 Aug;114(3):330-8
15286799
Am J Med Sci. 1993 Nov;306(5):282-6
8238081
Neuroscience. 1999;91(2):519-25
10366009
Cell Transplant. 2002;11(3):275-81
12075993
J Cereb Blood Flow Metab. 1988 Aug;8(4):449-61
2968987
J Neurol Sci. 1996 May;137(2):69-78
8782158
J Cereb Blood Flow Metab. 2003 Jul;23(7):780-5
12843782
Blood. 2000 May 1;95(9):2813-20
10779426
Brain Res. 1995 Jun 5;682(1-2):182-8
7552309
J Cereb Blood Flow Metab. 1981;1(1):53-60
7328138
Stroke. 1984 Jul-Aug;15(4):755-8
6464072
J Hematother Stem Cell Res. 2003 Jun;12(3):255-70
12857367
Stroke. 2004 Oct;35(10):2385-9
15345799
Cell Transplant. 2002;11(3):261-4
12075991
Stroke. 1998 Oct;29(10):2189-95
9756602
Cytotherapy. 2002;4(2):109-18
12006206
J Neurosci Res. 2003 Aug 1;73(3):296-307
12868063
Ann Neurol. 2003 Jan;53(1):10-20
12509843